MX2022005826A - Inhibidor de srebp que comprende un anillo central de tiofeno. - Google Patents

Inhibidor de srebp que comprende un anillo central de tiofeno.

Info

Publication number
MX2022005826A
MX2022005826A MX2022005826A MX2022005826A MX2022005826A MX 2022005826 A MX2022005826 A MX 2022005826A MX 2022005826 A MX2022005826 A MX 2022005826A MX 2022005826 A MX2022005826 A MX 2022005826A MX 2022005826 A MX2022005826 A MX 2022005826A
Authority
MX
Mexico
Prior art keywords
srebp
compound
thiophene
central ring
pharmaceutically acceptable
Prior art date
Application number
MX2022005826A
Other languages
English (en)
Inventor
Michael John Green
Barry Patrick Hart
Original Assignee
Capulus Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capulus Therapeutics Llc filed Critical Capulus Therapeutics Llc
Publication of MX2022005826A publication Critical patent/MX2022005826A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporciona en la presente descripción el compuesto (3-cloro-4-(4-(2-(2- hidroxipropan-2-il) piridin-4-il) tiofen-2-il) fenil) (4-hidroxipiperidin-1-il) metanona (Compuesto 1) y las sales, solvatos, tautómeros, isótopos o isómeros farmacéuticamente aceptables de este. También se proporcionan en la presente descripción métodos para inhibir un componente de la vía de la proteína de unión a elementos reguladores de esteroles (SREBP), tales como una SREBP o una proteína activadora de la escisión de SREBP (SCAP), mediante el uso del Compuesto 1, o una sal, solvato, tautómero, isótopo o isómero farmacéuticamente aceptable de este. Además, se proporcionan métodos para tratar un trastorno en un sujeto que lo necesita, tales como enfermedad hepática, esteatohepatitis no alcohólica, resistencia a la insulina o cáncer.
MX2022005826A 2019-11-13 2020-11-12 Inhibidor de srebp que comprende un anillo central de tiofeno. MX2022005826A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962935028P 2019-11-13 2019-11-13
US202062966356P 2020-01-27 2020-01-27
US202063056408P 2020-07-24 2020-07-24
PCT/US2020/060276 WO2021097122A1 (en) 2019-11-13 2020-11-12 Srebp inhibitor comprising a thiophene central ring

Publications (1)

Publication Number Publication Date
MX2022005826A true MX2022005826A (es) 2022-08-16

Family

ID=75912882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005826A MX2022005826A (es) 2019-11-13 2020-11-12 Inhibidor de srebp que comprende un anillo central de tiofeno.

Country Status (11)

Country Link
US (1) US20220356170A1 (es)
EP (1) EP4058014A4 (es)
JP (1) JP2023502604A (es)
KR (1) KR20220128335A (es)
CN (1) CN114945365A (es)
AU (1) AU2020381462A1 (es)
BR (1) BR112022008862A2 (es)
CA (1) CA3157442A1 (es)
MX (1) MX2022005826A (es)
TW (1) TW202128678A (es)
WO (1) WO2021097122A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112243374A (zh) 2018-01-29 2021-01-19 卡普勒斯疗法有限责任公司 包括6元中心环的srebp抑制剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3265457A1 (en) * 2015-03-04 2018-01-10 Medivation Technologies LLC Sterol regulatory element-binding proteins (srebps) inhibitors
CA2978627A1 (en) * 2015-03-04 2016-09-09 Medivation Technologies, Inc. Srebp blockers for use in treating liver fibrosis, elevated cholesterol and insulin resistance
EP3917513A4 (en) * 2019-01-28 2022-11-09 Capulus Therapeutics, LLC SREBP INHIBITORS WITH A THIOPHENE CENTER RING
AR118043A1 (es) * 2019-02-11 2021-09-15 Merck Patent Gmbh DERIVADOS DE INDAZOLIL-ISOXAZOL COMO INHIBIDORES DE c-KIT QUINASA
EP4058016A4 (en) * 2019-11-13 2023-12-20 Capulus Therapeutics, LLC THIOPHENE COMPOUNDS WITH CYCLIC AMIDES AND USES THEREOF

Also Published As

Publication number Publication date
AU2020381462A1 (en) 2022-06-02
WO2021097122A1 (en) 2021-05-20
TW202128678A (zh) 2021-08-01
US20220356170A1 (en) 2022-11-10
EP4058014A1 (en) 2022-09-21
CN114945365A (zh) 2022-08-26
KR20220128335A (ko) 2022-09-20
CA3157442A1 (en) 2021-05-20
JP2023502604A (ja) 2023-01-25
EP4058014A4 (en) 2023-12-13
BR112022008862A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
MX2020002060A (es) Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos.
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
MX2020007956A (es) Inhibidores de la proteína de unión al elemento regulador de esterol (srebp) que comprenden un anillo central de 6 miembros.
JP2018501226A5 (es)
PH12019502345A1 (en) Methods of treatment using a jak inhibitor compoud
MX2019008698A (es) Derivado de piridina como inhibidor de ask1 y metodo de preparacion y uso del mismo.
RU2008145225A (ru) Соединения индазола и способы ингибирования cd7
PH12019502425A1 (en) Crystalline forms of a jak inhibitor compound
TW200607505A (en) Fused heterocyclic kinase inhibitors
NO20072443L (no) Fungicide aktive ingredienskombinasjoner
NZ598582A (en) Novel phenol derivative having uricsuric effect
JP2018505876A5 (es)
EA201891578A1 (ru) Композиции 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил-2,2-дифторацетамида
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
JP2017511378A5 (es)
MX2020013694A (es) Compuestos heterocíclicos como inhibidores de trk.
EP2205088A4 (en) NAPHTHALIN-BASED INHIBITORS OF ANTI-APOPTOTIC PROTEINS
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
SG11201900298RA (en) Heterocyclic compound used as fgfr inhibitor
RU2003103780A (ru) Соединения фенилпиридазина и содержащие их лекарственные средства
WO2020159889A9 (en) Srebp inhibitors comprising a thiophene central ring
MX2022005826A (es) Inhibidor de srebp que comprende un anillo central de tiofeno.
EP4162937A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF PARKINSON'S DISEASE, COMPRISING A COMPOUND OF THE TYPE 2-(4-(1-HYDROXYPROPANE-2-YL)PHENYL)ISOINDOLIN-1-ONE
MX2020008610A (es) Agente terapeutico para carcinoma hepatocelular.
MX2009006528A (es) Sal de succinato de la 2-((4-(1-metil-4-(piridin-4-il)-1h-pirazol- 3-il)fenoxi)metil)quinolina.